Corporate Update: Aardvark Therapeutics Surges Amid FDA Relief on ARD‑101
Aardvark Therapeutics (AARD) advanced sharply, posting a 13.08 % increase in the 24‑hour window ending 09:08 AM Central Europe on Friday, 23 June 2026. The shares closed at approximately USD 3.95 on the major exchanges, reflecting a market capitalisation of USD 96.5 million and a liquidity of 21.9 million shares outstanding.
The rally follows the company’s announcement that the U.S. Food and Drug Administration has lifted the clinical hold on its Investigational New Drug (IND) application for ARD‑101, a small‑molecule appetite‑modulating therapy for Prader–Willi syndrome. Aardvark will resume Phase 3 HERO and open‑label extension studies, and it will hold a live investor conference call and webcast to present the data that led to the FDA’s decision. Earlier pauses were triggered by reversible ECG changes observed in a separate safety study; subsequent analyses have confirmed the absence of cardiac events at the tested doses, satisfying the FDA’s safety concerns.
Trading Dynamics
- Current Price – USD 3.95
- 24‑hour Volume – USD 963.1 k
- Market Cap – USD 96.5 mn
- Last 200‑Day SMA – USD 6.76
- 52‑Week High – USD 16.6 (22 January 2026)
- 52‑Week Low – USD 3.35 (27 March 2026)
Aardvark’s shares are trending upward from a recent 23.3 % decline since the end of May, indicating a potential rebound as investors weigh the regulatory relief and the company’s strategic pipeline.
Peer Performance Snapshot
| Ticker | % Change | Current Price | Market Cap (mn) |
|---|---|---|---|
| QMLS | +4.49 % | USD 3.41 | 114.1 |
| HUMA | +1.23 % | USD 0.41 | 114.2 |
| NERV | +0.42 % | USD 2.40 | 114.1 |
| ARMP | +12.75 % | USD 3.45 | 113.8 |
| VXRT | –2.17 % | USD 0.44 | 115.5 |
Vaxart’s slight decline underscores the broader volatility in the biotech sector, while Armata’s 12.75 % surge highlights the market’s appetite for companies with promising late‑stage assets.
Forward‑Looking Assessment
The FDA’s decision is a critical milestone that removes a regulatory roadblock, potentially accelerating the timeline for ARD‑101 to reach the market. Aardvark’s ability to leverage its safety data and maintain transparent communication with investors suggests a disciplined approach to risk management. Coupled with the company’s ongoing collaborations to develop hunger‑modulating therapies for rare genetic disorders, Aardvark is positioned to capitalize on a niche yet high‑impact therapeutic space.
Given the recent price action and the company’s strategic trajectory, the market appears poised for a measured but sustained uptrend, provided that subsequent clinical milestones are met without additional safety concerns.
